This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved — with conditions — Genentech‘s Polivy (polatuzumab vedotin-piiq), used in combination with Rituxan (rituximab) and bendamustine (a chemotherapy), to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who had gone through at least two prior therapies. The approval…
This post was originally published on this site Darolutamide in combination with androgen deprivation therapy (ADT) delays disease worsening in men with non-metastatic castration-resistant prostate cancer (nmCRPC) and stabilizes their quality of life without increasing the incidence of adverse events, new data from a Phase 3 trial shows. The findings were presented in an oral…
This post was originally published on this site The investigational immunotherapy AMG 420 lessened tumor burden and led to cancer disappearing in half of the patients with relapsed or refractory multiple myeloma who received the most effective dose in a Phase 1 clinical trial. The study, “Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line therapy for patients with metastatic or recurrent and inoperable head and neck squamous cell carcinoma (HNSCC) whose tumors express the PD-L1 factor. It also approved the treatment in combination with platinum chemotherapy — cisplatin…
This post was originally published on this site Adding an assessment of a woman’s clinical risk to Genomic Health‘s genomic test Oncotype DX to estimate the likelihood of breast cancer recurrence may spare more young women from having to undergo chemotherapy after surgery than originally thought. These findings come from a secondary analysis of the…
This post was originally published on this site Treatment with Tyvyt (sintilimab injection) was found safe and eased the tumor burden or led to cancer disappearance in nearly 3 out of 10 patients with relapsed or refractory classical Hodgkin’s lymphoma, according to follow-up results of a Phase 2 clinical trial in China. Trial findings, “Sintilimab…
This post was originally published on this site First-line treatment with Keytruda (pembrolizumab) in combination with chemotherapy prolongs the survival of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), compared to standard of care treatment, a final analysis of a Phase 3 trial shows. The findings were presented during an oral presentation,…
This post was originally published on this site I could smell cleanliness when I opened my front door. Lemon. Pine. The glorious absence of dust. It’s that elusive moment right after my housecleaners leave and my home looks like it does in my imagination: orderly and spotless. My crockpot hints that dinner is on the…
This post was originally published on this site Isatuximab, a potential therapeutic antibody, can improve survival in relapsed/refractory multiple myeloma patients being given a standard treatment consisting of Pomalyst (pomalidomide) and dexamethasone (brand names include Decadron and Dexpak), results of a pivotal Phase 3 clinical trial suggest. The data were presented at the 2019 annual meeting of the American…
This post was originally published on this site People with the non-germinal center subtype of diffuse large B-cell lymphoma (non-GCB DLBCL) respond well to initial treatment with Rituxan (rituximab), Imbruvica (ibrutinib), and Revlimid (lenalidomide) — so well that chemotherapy, the standard of treatment, might not be necessary in some cases. Results from the Smart Start…
